shutterstock_1667502061_tada_images
Tada Images / Shutterstock.com
1 July 2021Big PharmaAlex Baldwin

Minerva: less risk for inventors, more work for the courts

The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
22 April 2021   The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.
Big Pharma
2 February 2021   A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

More on this story

Big Pharma
22 April 2021   The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.
Big Pharma
2 February 2021   A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

More on this story

Big Pharma
22 April 2021   The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.
Big Pharma
2 February 2021   A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.